Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM27ZJG)

Drug Name
AKST4290 Drug Info
Synonyms
Lazucirnon; ALK4290; ALK-4290; AKST4290; 1251528-23-0; Lazucirnon [USAN]; ALK429; AKST-4290; R0T9LLR4TN; BI144807; ALK-429; Lazucirnon (USAN); 2-[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-N,N,6-trimethylpyridine-4-carboxamide; 2-((((2R)-1-(1-((4-Chloro-3-methylphenyl)methyl)-4-piperidinyl)-5-oxo-2-pyrrolidinyl)carbonyl)amino)-N,N,6-trimethyl-4-pyridinecarboxamide; 4-Pyridinecarboxamide, 2-((((2R)-1-(1-((4-chloro-3-methylphenyl)methyl)-4-piperidinyl)-5-oxo-2-pyrrolidinyl)carbonyl)amino)-N,N,6-trimethyl-; LAZUCIRNON [INN]; UNII-R0T9LLR4TN; SCHEMBL1668125; CHEMBL3670800; GTPL10653; BDBM123072; GLXC-26875; WHO 11481; AKOS040755379; DB15269; MS-29506; Example 11 [WO2012045803A1]; HY-136788; CS-0133685; D11741; US8742115, 11; 2-{(2R)-1-[1-(4-Chloro-3-methylbenzyl)piperidin-4-yl]-5-oxopyrrolidin-2-carboxamido}-N,N,6-trimethylpyridine-4-carboxamide
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 2 [1]
Cross-matching ID
PubChem CID
59534386
TTD Drug ID
DM27ZJG

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 3 (CCR3) TTD3XFU CCR3_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
C-C chemokine receptor type 3 (CCR3) DTT CCR3 3.982 4.271 3.838 3.609
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-C chemokine receptor type 3 (CCR3) DTT CCR3 2.97E-06 -0.44 -0.48
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04369430) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment. U.S.National Institutes of Health.
2 SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2022 Jun 1;42(6):1038-1046.